Financial Synergies Wealth Advisors Inc. Makes New Investment in Johnson & Johnson $JNJ

Key Points

• Financial Synergies Wealth Advisors Inc. acquired a new position in Johnson & Johnson, purchasing 6,651 shares valued at approximately $1,016,000 in the second quarter.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, representing a 2.7% yield, with an upcoming ex-dividend date of November 25th.
• Several analysts have upgraded their ratings for Johnson & Johnson, with price targets reaching as high as $215.00, reflecting a positive outlook for the company’s stock.

Financial Synergies Wealth Advisors Inc. acquired a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,651 shares of the company's stock, valued at approximately $1,016,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson during the first quarter valued at $218,000. GAMMA Investing LLC lifted its stake in shares of Johnson & Johnson by 48.0% during the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock valued at $7,215,000 after acquiring an additional 14,118 shares during the period. Monte Financial Group LLC lifted its stake in shares of Johnson & Johnson by 1.3% during the first quarter. Monte Financial Group LLC now owns 36,636 shares of the company's stock valued at $5,769,000 after acquiring an additional 464 shares during the period. Finally, Weaver Capital Management LLC lifted its stake in shares of Johnson & Johnson by 30.9% during the first quarter. Weaver Capital Management LLC now owns 12,261 shares of the company's stock valued at $2,033,000 after acquiring an additional 2,891 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.3%

Shares of Johnson & Johnson stock opened at $193.78 on Tuesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The business has a 50-day moving average of $180.89 and a two-hundred day moving average of $165.18. The company has a market capitalization of $466.68 billion, a P/E ratio of 18.70, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio is 50.19%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Daiwa Capital Markets raised Johnson & Johnson from a "neutral" rating to an "outperform" rating and set a $203.00 price target on the stock in a research note on Monday. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Weiss Ratings upgraded Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. HSBC upped their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the company a "buy" rating in a report on Thursday, October 16th. Finally, The Goldman Sachs Group upped their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $200.06.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.